Journal Mobile Options
Table of Contents
Vol. 22, No. 4, 2002
Issue release date: July–August 2002
Am J Nephrol 2002;22:385–388
(DOI:10.1159/000065233)

Dermatomyositis Associated with Membranous Nephropathy in a 43-Year-Old Female

Akashi Y. · Inoh M. · Gamo N. · Kinashi M. · Ohbayashi S. · Miyake H. · Kurata N.
aDepartment of Internal Medicine, Kinashi Ohbayashi Hospital and bMiyake Clinic, Takamatu, Kagawa, Japan

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

A 43-year-old woman was admitted to our hospital for myalgic pain and erythema of the face and thighs. She had been diagnosed with dermatomyositis at another hospital 8 years earlier and proteinuria had developed suddenly. Renal histological examination revealed membranous nephropathy. Membranous nephropathy associated with dermatomyositis is very rare. To date, malignant disease has not been detected in our patient, but the serum level of CA125, a tumor marker, has been elevated to 1,097 U/ml. The increased CA125 level is related to the degree of proteinuria and after prednisolone and cyclosporine therapy, proteinuria and the CA125 level gradually decreased.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Marie I, Hatron PY, Hachulla E, Wallaert B, Michon-Pasturel U, Devulder B: Pulmonary involvement in polymyositis and in dermatomyositis. J Rheumatol 1998;25:1336–1343.
  2. Fukui H, Kimura T, Nakabayashi K, Nagasawa T: Dermatomyositis associated with immune-complex type nephritis induced by tubular epithelial antigen. Jpn J Nephrol 1976;18:523–533.

    External Resources

  3. Rose JD: Membranous glomerulonephritis, dermatomyositis, and bronchial carcinoma. Br Med J 1979;ii:641.
  4. Hosoda Y, Yoshida S, Mimori T, Toguchi T, Inada S, Tomii M, Yamagata H, Akizuki M, Abe T: Polymyositis associated with interstitial pulmonary fibrosis and glomerulonephritis. A report of two autopsy cases. Ryumachi 1981;21:183–188.

    External Resources

  5. Moriyama A, Uruta Y, Yamaguchi Y, Fukuzaki M, Uchida Y, Yasumoto Y, Yamashita W, Harada R, Ohsaki K, Nakajima A: A case of immune-complex type glomerulonephritis associated with dermatomyositis (in Japanese). J Jpn Soc Intern Med 1989;78:994–995.
  6. Makino H, Hirata K, Matsuda M, Amano T, Ota Z: Membranous nephropathy developing during the course of dermatomyositis. J Rheumatol 1994;21:1377–1378.
  7. Soylu A, Kavukcu S, Turkmen M, Saroglu S: Dermatomyositis with membranous nephropathy. Turk J Pediatr 2001;43:143–145.

    External Resources

  8. Brown H, Steven M: Myositis and malignancy: Is there a true association? Hosp Med 1999;60:51–53.

    External Resources

  9. Nakanishi K, Cualing H, Husseinzadeh N: Dermatomyositis as a presenting symptom of ovarian cancer. Obstet Gynecol 1999;94:836–838.
  10. DiBaise JK, Donovan JP: Markedly elevated CA125 in hepatic cirrhosis. J Clin Gastroenterol 1999;28:159–161.
  11. Zuckerman E, Lanir A, Sabo E, Zuckerman TR, Matter I, Yeshurun D, Elder S: Cancer antigen 125; a sensitive marker of ascites in patients with liver cirrhosis. Am J Gastroenterol 1999;94:1613–1618.
  12. Sevinc A, Buyukberber S, Sari R, Turk HM, Ates M: Elevated serum CA125 levels in patients with nephrotic syndrome-induced ascites. Anticancer Res 2000;20:1201–1204.
  13. Rostoker G, Belghiti D, Ben Maadi A, Remy P, Lang P, Weil B, Lagrue G: Long-term cyclosporin A therapy for severe idiopathic membranous nephropathy. Nephron 1993;63:335–341.
  14. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271–1277.


Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00